Coverage dated October 12, 2021 to October 14, 2021
FDA panel backs booster shot for J&J COVID-19 vaccine
Headline from Daily Journal Online, on the newest of 3 developments
A panel of U.S. health advisers endorsed booster doses of Johnson & Johnson's single-shot COVID-19 vaccine Friday.
Daily Journal Online's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.
Developments in this update
3 dated developments, oldest first, newest marked. Each is named by one outlet's own headline; open its reports to see every outlet that covered it.
FDA report finds J&J COVID-19 booster beneficial, despite limited data
Headline from The Hill ·
FDA panel endorses lower-dose Moderna COVID shot for booster
Headline from KAAL Rochester ·
Newest
FDA panel backs booster shot for J&J COVID-19 vaccine
A second dose of Johnson & Johnson's coronavirus vaccine is likely beneficial to recipients, the Food and Drug Administration (FDA) said Wednesday, thoughthe data is extremely limited.
WASHINGTON (AP) — The Food and Drug Administration is wrestling with whether and when to offer another dose of the single-shot Johnson & Johnson COVID-19 vaccine, while a new study
WASHINGTON (AP) — The Food and Drug Administration said Wednesday it is wrestling with whether and when recipients of the single-shot Johnson & Johnson COVID-19 vaccine need another dose
Johnson & Johnson has asked the Food and Drug Administration to authorize a booster for people 18 and older six months after initial immunization, with an option to vaccinate after two months.
A booster of Johnson & Johnson’s Covid-19 vaccine showed signs of significantly bolstering the immune defenses of study subjects, federal health regulators said Wednesday.
The FDA is wrestling with how to decide on booster doses of the single-shot Johnson & Johnson COVID-19 vaccine. Other manufacturers want to offer boosters six months after primary vaccination. But J&J proposed a range of times, from two months to six months.
U.S. health advisers are debating if millions of Americans who received Moderna vaccinations should get a booster shot -- this time, using half the original dose.
U.S. health advisers said Thursday that some Americans who received Moderna’s COVID-19 vaccine at least six months ago should get a half-dose booster to rev up protection against the coronavirus.
U.S. health advisers are debating if millions of Americans who received Moderna vaccinations should get a booster shot — this time, using half the original dose. The discussion began Thursday and continues Friday.
The endorsement is a crucial step before the U.S. can start giving third shots to some of the millions of Americans who originally received Moderna’s vaccine.
WASHINGTON — Millions of Americans who received Moderna’s two-shot COVID-19 vaccine are expected to be eligible soon for booster shots, after a federal advisory panel on Thursday recommended a third dose for older and higher-risk adults as well as certain workers.
The panel recommended giving the shots at least six months after initial immunization. Its vote is not binding, but the FDA normally follows the recommendations of its advisory committees.
If approved, the Moderna and Johnson & Johnson COVID-19 boosters will go to the FDA for final approval. The CDC would determine who gets the shot and when.
A federal advisory panel is meeting Thursday and Friday to consider whether to back booster shots of both the Johnson & Johnson and Moderna COVID-19 vaccines. The FDA committee will also consider whether it’s OK to mix and match vaccines.
By Maggie Fox and Jamie Gumbrecht, CNN Vaccine advisers to the US Food and Drug Administration voted unanimously Thursday to recommend emergency use authorization of a booster dose of Moderna’s Covid-19 vaccine.
The Food and Drug Administration is set to hold crucial meetings over the next two days to decide whether to issue booster shots of Johnson & Johnson and Moderna COVID vaccines. Follow Newsweek's liveblog for all the latest.
